Syzygium aromaticum as a possible source of SARS-CoV-2 main protease inhibitors: Evidence from a computational investigation
Journal: Journal of Advanced Biotechnology and Experimental Therapeutics (Vol.5, No. 1)Publication Date: 2022-01-10
Authors : Chayan Ali; Anjumana Jannati Nur; Rizone Al Hasib; Rubaeit All Rakib; Mst. Shanzeda Khatun; Md Mafizur Rahman; Shahedur Rahman; Khasrul Alam; Abdullah Al Mashud; Mohammad Abu Hena Mostofa Jamal;
Page : 218-228
Keywords : SARS-CoV-2; COVID-19; main protease; inhibitors; docking; molecular dynamics simulation.;
Abstract
SARS-CoV-2, a new and fast circulating coronavirus strain, infected over 214 countries and territories worldwide and caused global health emergencies. The absence of appropriate medicines and vaccinations has further complicated the condition. SARS-CoV-2 main protease (Mpro) is crucial for its propagation, and it is considered a striking target. This study used several computational approaches to determine the probable antagonist of SARS-CoV-2 Mpro from bioactive phytochemicals of Syzygium aromaticum. A total of 20 compounds were screened through in silico approach. The molecular dynamics simulation studies were then carried out for further insights. We found crategolic acid, oleanolic acid, and kaempferol have considerable binding affinity and important molecular contacts with catalytic pocket residues, His41-Cys145. The pharmacological properties through ADMET analysis also showed that these compounds could be used as safe drug candidates. The molecular dynamics simulation study further confirmed these compound's stability with Mpro. However, further detailed in-vitro and in-vivo analyses are compulsory to evaluate the real potentiality of identified compounds.
Other Latest Articles
- Mucormycosis (black fungus) and its impact on the COVID-19 patients: An updated review
- Nata as a source of dietary fiber with numerous health benefits
- Molecular and immunological activity of Terminalia chebula extracts
- Impact of process validation and equipment qualification in production of bio-therapeutics
Last modified: 2022-01-31 23:56:52